EV/DNG (Qlaira, BAY86-5027, SH T00658K)

DRUG4 trials

Sponsors

Bayer

Conditions

ContraceptionOvulation Inhibition

Phase 2

Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive

CompletedNCT00185224

BayerContraception

Start: 2005-03-31End: 2006-03-31Updated: 2011-07-15

Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens

CompletedNCT00805415

BayerOvulation Inhibition

Start: 2003-03-31End: 2004-02-29Updated: 2011-07-15

Phase 3

Study to Investigate Efficacy and Safety of a New Oral Contraceptive

CompletedNCT00185289

BayerContraception

Start: 2004-04-30End: 2006-07-31Updated: 2011-07-15

Comparative Cycle Control Europe

CompletedNCT00185367

BayerContraception

Start: 2005-03-31End: 2006-09-30Updated: 2011-07-15

Related Papers

Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

2011-01-0161 citations